Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized placebo-controlled study of Octagam 10% in dermatomyositis
2016-002902-37Phase 3Completed
- Sponsor
- Octapharma
- Start
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Human normal immunoglobulin G in dermatomyositis (DM), sponsored by Octapharma. Started Sep 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2016-002902-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002902-37.